Curasight A/S reports positive preclinical results with uTREAT[®] in lung cancer (NSCLC)
· Preclinical studies show uTREAT[®] effective in treating non-small cell lung cancer (NSCLC) · Data follows recent announcement of positive preclinical results within glioblastoma and supports hypothesis that uTREAT[®] has treatment potential in additional solid tumors · Data highlights potential of company’s uPAR theranostic platform to combine diagnosis (uTRACE[®]) with more gentle and targeted treatment (uTREAT[®]) Copenhagen, October 18, 2023 - Curasight A/S (“Curasight” or “the Company” – TICKER: CURAS) is pleased to announce preclinical data demonstrating preclinical proof